|
|
|
市場調査レポート
医療分野における学術界と産業界の提携における新たな戦略
New Strategies in Academic-Industry Collaborations
|
Abstract
Introduction
Major pharmaceutical companies are showing increased interest in directly
sponsoring academic research to access innovation and fill dwindling
pipelines. Recent agreements involve higher levels of collaboration and
funding, are broader in scope, and focus on more-basic research than
previously. This increased collaboration among scientists performing basic
research, clinical researchers, and drug developers will accelerate the shift
to translational medicine and has the potential to yield great benefits to
patients and society.
Questions Answered in This Report
- Pharmaceutical companies have recently formed numerous collaborations with
large research institutions. What factors are driving this interest? What
are the key features of recent collaborative agreements? How does each
organization benefit from these arrangements?
- The environment of academic technology transfer to industry is
changing. What impact has the Bayh-Dole Act had on technology transfer? How
do academic institutions manage academicindustry relationships? Which
institutions are leading in innovation and commercialization of technology?
- Drug developers are experimenting with different approaches to
academic-industry relations. Which key collaborations illustrate these new
approaches? What strategic interests of the pharmaceutical industry do these
agreements serve? How will universities and companies measure success?
- Relationships between academia and industry present special challenges.
How do the missions and goals of academia and industry differ? What
conflicts can arise with respect to industry funding of academic researchers?
How can institutions and companies manage these differences?
Scope
- Factors in academic-industry collaborations: historical
relationships, dwindling pharmaceutical pipelines, diminishing federal funding
for academia.
- Technology transfer: impact of Bayh-Dole, tech transfer offices,
inventions and innovation, challenges in academic-industry relationships.
- New approaches in academic-industry relationships:
close-collaboration, broad-scope, early-stage research.
- Translational medicine: theme of collaborations, goals, motivations.
- Drug discovery centers: academic centers for dug discovery,
industry discovery centers, pharmaceutical incubators.
- Notable collaborators: AstraZeneca, Centocor, GlaxoSmithKline,
Janssen Pharmaceutica, Merck, Novartis, Pfizer; Columbia University Medical
Center, Harvard Medical School, Harvard Stem Cell Institute, Immune Disease
Institute, MIT, University of California, San Francisco, University of
Michigan, Vanderbilt University, Washington University.
Mentioned in This Report
- Abbott Laboratories
- Astellas Pharma
- AstraZeneca
- Biogen Idec
- Boston College
- Boston University
- Brandeis University
- Brigham and Women' s Hospital
- Bristol-Myers Squibb
- California Institute of Technology
- Cellartis
- Center for Applied Cancer Science
- Centocor
- Columbia University Medical Center
- Daiichi Sankyo
- Dana-Farber Cancer Institute
- Eli Lilly
- Eisai
- GE Healthcare
- Genentech
- Genzyme
- GlaxoSmithKline
- Global Alliance for TB Drug Development
- Harvard Medical School
- Harvard Stem Cell Institute
- Icagen
- Immune Disease Institute
- Janssen Pharmaceutica
- Japan Science and Technology Agency
- Johns Hopkins University School of Medicine
- Johnson & Johnson
- Massachusetts Institute of Technology
- MD Anderson Cancer Center
- Medical Research Council
- Merck
- Merck KGaA
- Northeastern University
- Novartis
- Novo Nordisk
- Osiris Therapeutics
- Pfizer
- Roche
- SanofiPasteur
- Schering-Plough
- Shanghai Institute for Biological Sciences
- Stanford University
- Statens Serum Institute
- Takeda
- Tufts University
- University of California, Berkeley
- University of California, San Diego
- University of California, San Francisco
- University of Cambridge
- University of London
- University of Massachusetts Medical School
- University of Michigan
- University of Texas
- Vanderbilt University
- Walter and Eliza Hall Institute
- Washington University
- Wyeth
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction to Academic-Industry Collaborations
- Impact of Bayh-Dole on Technology Transfer to Industry
- Bayh-Dole and the Rise of Technology Transfer Offices
- Academia: A Rich Source of Novel Inventions and Innovation for Drug
Discovery
- Challenges in Academic-Industry Relationships
- New Approaches in Academic-Industry Collaborations
- Collaborative Models
- Translational Medicine
- Academic and Industry Centers for Drug Discovery.
- Academic Drug Discovery Centers
- Pharmaceutical R&D Centers
- Pharmaceutical R&D Incubators
- Academic-Industry Collaborations of Note
- Merck/Harvard Medical School
- GSK/Harvard Stem Cell Institute
- GSK/Immune Disease Institute
- AstraZeneca/Columbia University Medical Center
- Pfizer/ Washington University
- Pfizer/University of California, San Francisco
- Janssen Pharmaceutica/Vanderbilt University
- Centocor/University of Michigan
- Novartis/MIT
- Outlook for Academic-Industry Collaborations
Tables
- 1. Select Academic Drug Discovery Centers
- 2. Select Pharmaceutical R&D Centers
- 3. Select Academic-Industry Collaborations
- 4. R&D Expenditures of Top Pharmaceutical Companies, 2008
Figures
- 1. Annual National Institutes of Health Budget, 2001-2010
- 2. Staffing of U.S. Technology Transfer Offices, 1998-2007
- 3. Relationships Among Academic Research Institutions and External Entities
- 4. Industrial Research Support for U.S. Universities, Hospitals, and
Research Institutions
- 5. Top 20 Academic Biotechnology Patent Filers, 2002-2006
|
 |
